A review of different methods used for quantification and assessment of FDG-PET/CT in multiple myeloma. Issue 4 (31st January 2022)

• Record Type: Journal Article
• Authors: Zirakchian Zadeh, Mahdi; Ayubcha, Cyrus; Raynor, William Y.; Werner, Thomas J.; Alavi, Abass
• Is Part Of: Nuclear medicine communications. Volume 43:Issue 4(2022)
• Page Start: 378
• Page End: 391
• Publication Date: 2022-01-31
• Subjects: 18F-fluorodeoxyglucose -- PET metrics -- multiple myeloma -- PET/CT -- PET -- quantification; Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000001528
• Languages: English
• ISSNs: 0143-3636

Abstract

Abstract : The quantification of positron emission tomography/computed tomography (PET/CT) in multiple myeloma (MM) is challenging. Different methods of PET/CT quantification for assessment of fluorodeoxyglucose (FDG) uptake in myeloma patients have been suggested. This is the first review article that focuses on the advantages and disadvantages of each approach. Use of the maximum standardized uptake value (SUVmax ) showed some promise in prognostic stratification of MM patients. However, it is affected by noise and time of flight and is subject to high variability. Volumetric PET metrics such as total lesion glycolysis and metabolic tumor volume are other proposed approaches. The high number of osteolytic lesions in MM patients makes this approach difficult in clinical practice. In addition, evaluation of small focal lesions is subject to partial volume correction. CT-based segmentation for assessment of FDG radiotracer is recently introduced. The methodologies are highly reproducible, but the clinical values of the approaches are unclear and still under investigation. We also discuss the Italian Myeloma criteria for PET Use (IMPeTUs), which is a qualitative approach, as a point of comparison. The reproducibility of IMPeTUs depends heavily on the level of user experience. We recommend further studies for assessing the prognostic significance of CT-threshold approaches in the assessment of MM patients.